Company Overview of Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a drug development company, develops small molecule therapeutics for the treatment of inflammatory and cardiovascular diseases. Its product includes a short-acting calcium channel antagonist for the treatment of transient cardiovascular conditions, such as atrial arrhythmias and angina. The company was founded in 2003 and is based in Montreal, Canada.
6100 Royalmount Avenue
Montreal, QC H4P 2R2
Founded in 2003
Key Executives for Milestone Pharmaceuticals Inc.
Chief Executive Officer and Director
Vice President of Chemistry & Manufacturing
Vice President of Drug Development
Compensation as of Fiscal Year 2014.
Milestone Pharmaceuticals Inc. Key Developments
Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND
Jan 12 15
Milestone Pharmaceuticals Inc. announced that it received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 study of MSP-2017 for the treatment of acute episodes of Paroxysmal Supraventricular Tachycardia (PSVT). The trial is expected to begin patient enrollment in early 2015. The trial design cleared by FDA is a multiple arm Phase 2, multi-center, placebo-controlled study of intranasal administration of MSP-2017 for the conversion of PSVT to sinus rhythm. The primary objective of this study will be to demonstrate the superiority of at least one dose of intranasal MSP-2017 over placebo in terminating PSVT induced in an electrophysiology laboratory. MSP-2017 is a novel and potent short-acting calcium channel antagonist for the treatment of PSVT, a potentially debilitating cardiac arrhythmia. MSP-2017 has successfully completed Phase 1 studies and is scheduled to start Phase 2 in First Quarter 2015. The product is being developed as a patient self-administered nasal spray to terminate PSVT episodes at-home. MSP-2017 has a rapid onset and reaches pharmacologically relevant plasma levels within 5 minutes of administration. MSP-2017 is designed to be short-acting, allowing it to be metabolized quickly after resolution of the PSVT episode. MSP-2017 will allow patients to terminate their PSVT episodes at home and avoid ER visits. MSP-2017 is intended to address a significant unmet medical need due to the lack of convenient, rapid, safe and effective self-administered products for the treatment of PSVT episodes in the home setting.
Milestone Pharmaceuticals Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 10:30 AM
Dec 18 14
Milestone Pharmaceuticals Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 10:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Milestone Pharmaceuticals, Inc. Announces Positive Phase 1 Data for MSP-2017 and Supports Advancement into Phase 2 in PSVT Patients
Dec 2 14
Milestone Pharmaceuticals Inc. announced data from a Phase 1 clinical trial conducted in Melbourne, Australia of MSP-2017, a novel calcium channel antagonist for the potential treatment of paroxysmal supraventricular tachycardia (PSVT). The results demonstrated that an intra-nasal formulation of MSP-2017 was well tolerated at single doses up to and including 140 mg with an excellent safety profile, desirable PK properties including rapid onset, and validating proof of concept by PR interval prolongation as measured by ECG. Milestone expects to initiate a Phase 2 clinical trial of MSP-2017 in patients with PSVT during the first half of 2015. The Phase 1 clinical trial included a randomized, double-blind, placebo-controlled, single ascending-dose study in 56 healthy volunteers. The primary objective of the study was to evaluate the safety, tolerability and pharmacokinetics of two intranasal formulations of MSP-2017 in a crossover design given as a single dose to seven successive cohorts of 8 healthy subjects each. All adverse events were mild in nature and no serious adverse events were reported. The Phase 1 study was undertaken following promising results in the preclinical evaluation of MSP-2017. In a series of in vivo experiments, MSP-2017 exhibited prolongation of the PR interval as measured by ECG. These results suggest MSP-2017 can impact AV nodal conduction, and support the potential of MSP-2017 to treat PSVT episodes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|